Design decisions can make or break reimbursement success. Learn why U.S. payment systems should influence your MedTech product development strategy.
U.S. payers don’t define “value” the same way as clinicians or investors. This article breaks down how payers assess value — and how early-stage MedTech startups can build compelling strategies for reimbursement success.
Why do better technologies struggle for reimbursement while outdated ones thrive? Discover the hidden bias in payer decision-making—and why second movers in MedTech face steeper evidence hurdles than the first.
FDA clearance is a milestone—not the finish line. Why reimbursement hurdles follow right after.